Chemotherapy-associated neutropenic fever
Conditions
Interventions
Observation group:None
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Visits from January 1, 2021 to June 30, 2023; 2.Patients with confirmed tumors, including but not limited to breast cancer, gynecological tumors, bowel cancer, lung cancer, lymphoma, esophageal cancer, gastric cancer, osteosarcoma, head and neck tumors, have been confirmed by imaging and histopathology; 3.Patients treated with chemotherapy;
Exclusion criteria
Exclusion criteria: 1.Patients with bone marrow invasion; 2.The clinical data are untrue and incomplete;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Utilization rate of G-CSF for primary prevention and secondary prevention;Use rate of therapeutic G-CSF in patients with FN; | — |
Secondary
| Measure | Time frame |
|---|---|
| According to geographical region, city class, hospital type, tumor type, chemotherapy purpose, chemo;Incidence and risk level of FN in each chemotherapy cycle;Each chemotherapy cycle was grade 3 (0.5*10^9/L<=ANC < 1.0*109/L) and grade 4 (ANC < 0.5×10^9/L) Inci;Whether to reduce the dose of chemotherapy regimen, delay chemotherapy, or change chemotherapy regim;Hospitalization rate;Length of stay;Whether to use antibiotics prophylactically; | — |
Countries
China
Contacts
Public ContactSuxia Luo
Henan Cancer Hospital
Outcome results
None listed